Q: How does Harvoni work?

Mechanism of Action Harvoni contains two active ingredients, ledipasvir and sofosbuvir, which are classified as direct-acting antivirals. These medications work by targeting specific proteins the hepatitis C virus (HCV) uses to replicate itself within the body. How the Ingredients Work Ledipasvir: This component blocks a protein called NS5A. The virus requires this protein to copy its genetic material and to assemble new virus particles. Sofosbuvir: This component is a polymerase inhibitor. It interferes with an enzyme called NS5B RNA polymerase, which the virus uses to build new strands of RNA. By providing a faulty building block, sofosbuvir stops the virus from completing its genetic code. By attacking the virus at two different stages of its life cycle, Harvoni prevents the hepatitis C virus from making copies of itself. As the treatment progresses, the viral load in the bloodstream decreases. The goal of this treatment is to reduce the virus to undetectable levels, effectively clearing the infection from the body.

Q: What are the active ingredients in Harvoni?

The active ingredients in Harvoni are sofosbuvir and ledipasvir .

Q: What are the side effects of Harvoni?

Common side effects of Harvoni may include: Fatigue Headache Nausea Always consult with a healthcare professional about potential side effects.

Q: Is Harvoni safe during pregnancy and breastfeeding?

Pregnancy There are no adequate studies on the use of Harvoni in pregnant women. Animal studies using doses much higher than those recommended for humans did not show evidence of harm to the fetus. However, because animal data do not always predict human outcomes, Harvoni is generally only recommended during pregnancy when the potential benefit justifies the potential risk. If Harvoni is used in a treatment regimen that includes ribavirin, extreme caution is required. Ribavirin is known to cause significant birth defects and fetal death. It must not be used by pregnant women or by men whose female partners are pregnant. Breastfeeding It is not known if the active ingredients in Harvoni, ledipasvir and sofosbuvir, pass into human breast milk. While these substances have been found in the milk of lactating animals, human data are unavailable. Decisions regarding breastfeeding while taking Harvoni should involve a discussion with a healthcare provider to weigh the benefits of breastfeeding against the mother's need for the medication and any potential risks to the infant.

Q: What forms and strengths does Harvoni come in?

Harvoni is provided in the following oral forms: Film-coated tablets: These are solid tablets intended to be swallowed whole. Oral pellets: These are supplied in packets. This form is intended for patients who have difficulty swallowing tablets and is typically sprinkled on soft food before consumption.

Q: What is the FDA approval status of Harvoni?

FDA Approval and Indications Harvoni, a combination of ledipasvir and sofosbuvir, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) genotypes 1, 4, 5, or 6. It is indicated for use in adults and pediatric patients 3 years of age and older. The medication is used for patients without cirrhosis or with compensated cirrhosis, and in combination with ribavirin for those with decompensated cirrhosis. It is also approved for certain patients co-infected with HIV-1 and for liver transplant recipients. Boxed Warning The FDA requires a boxed warning for Harvoni due to the risk of hepatitis B virus (HBV) reactivation . In patients infected with both HCV and HBV, starting treatment with direct-acting antivirals like Harvoni may cause the hepatitis B virus to become active again. This reactivation can result in serious liver injury, liver failure, or death. Healthcare providers are required to screen all patients for evidence of current or prior HBV infection before beginning therapy and monitor for flare-ups during and after treatment. Safety Communications The FDA has issued safety communications regarding the use of Harvoni with certain other medications. A significant concern involves the risk of serious symptomatic bradycardia (a dangerously slow heart rate) when Harvoni is taken in combination with amiodarone, a drug used to treat heart rhythm disorders. This interaction can be life-threatening and may require medical intervention or the use of a pacemaker. Additionally, the FDA monitors adverse event reports to identify potential new safety signals, such as skin reactions or other systemic issues, as part of its ongoing regulatory oversight.

Question 1

What is Harvoni?

Accepted Answer

Harvoni is a prescription medication that contains two active ingredients, ledipasvir and sofosbuvir. These medications belong to a class of drugs known as direct-acting antivirals.

This combination therapy works by interfering with the proteins the hepatitis C virus needs to grow and reproduce. By blocking these proteins, the medication helps reduce the amount of the virus in the body and may eventually clear the infection.

Question 2

What is Harvoni used for?

Accepted Answer

Harvoni is used to treat chronic hepatitis C virus infection.

Question 3

How does Harvoni work?

Accepted Answer

Mechanism of Action

Harvoni contains two active ingredients, ledipasvir and sofosbuvir, which are classified as direct-acting antivirals. These medications work by targeting specific proteins the hepatitis C virus (HCV) uses to replicate itself within the body.

How the Ingredients Work

Ledipasvir: This component blocks a protein called NS5A. The virus requires this protein to copy its genetic material and to assemble new virus particles.
Sofosbuvir: This component is a polymerase inhibitor. It interferes with an enzyme called NS5B RNA polymerase, which the virus uses to build new strands of RNA. By providing a faulty building block, sofosbuvir stops the virus from completing its genetic code.

By attacking the virus at two different stages of its life cycle, Harvoni prevents the hepatitis C virus from making copies of itself. As the treatment progresses, the viral load in the bloodstream decreases. The goal of this treatment is to reduce the virus to undetectable levels, effectively clearing the infection from the body.

Question 4

What are the active ingredients in Harvoni?

Accepted Answer

The active ingredients in Harvoni are sofosbuvir and ledipasvir.

Question 5

What are the side effects of Harvoni?

Accepted Answer

Common side effects of Harvoni may include:

Fatigue
Headache
Nausea

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Harvoni?

Accepted Answer

Harvoni belongs to the HCV NS5A inhibitor and NS5B polymerase inhibitor drug class.

Question 7

What is the dosage of Harvoni and how do I take it?

Accepted Answer

Harvoni is usually taken once a day at the same time each day. It can be taken with or without food. It is important to follow the schedule provided by a healthcare professional and to complete the full course of treatment, even if symptoms improve quickly.

Administration Methods

This medication is available in different forms, including tablets and oral pellets:

Tablets: These should be swallowed whole.
Oral Pellets: Pellets can be swallowed directly or sprinkled onto a small amount of non-acidic soft food, such as pudding or mashed potatoes. The mixture should be swallowed immediately without chewing the pellets.

Missed Doses

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not take two doses at the same time to make up for a missed one.

Treatment Duration

The length of treatment varies depending on the specific condition being treated and the patient's previous treatment history. It is common for treatment to last for several weeks.

Question 8

Is Harvoni safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate studies on the use of Harvoni in pregnant women. Animal studies using doses much higher than those recommended for humans did not show evidence of harm to the fetus. However, because animal data do not always predict human outcomes, Harvoni is generally only recommended during pregnancy when the potential benefit justifies the potential risk.

If Harvoni is used in a treatment regimen that includes ribavirin, extreme caution is required. Ribavirin is known to cause significant birth defects and fetal death. It must not be used by pregnant women or by men whose female partners are pregnant.

Breastfeeding

It is not known if the active ingredients in Harvoni, ledipasvir and sofosbuvir, pass into human breast milk. While these substances have been found in the milk of lactating animals, human data are unavailable. Decisions regarding breastfeeding while taking Harvoni should involve a discussion with a healthcare provider to weigh the benefits of breastfeeding against the mother's need for the medication and any potential risks to the infant.

Question 9

What forms and strengths does Harvoni come in?

Accepted Answer

Harvoni is provided in the following oral forms:

Film-coated tablets: These are solid tablets intended to be swallowed whole.
Oral pellets: These are supplied in packets. This form is intended for patients who have difficulty swallowing tablets and is typically sprinkled on soft food before consumption.

Question 10

What is the FDA approval status of Harvoni?

Accepted Answer

FDA Approval and Indications

Harvoni, a combination of ledipasvir and sofosbuvir, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) genotypes 1, 4, 5, or 6. It is indicated for use in adults and pediatric patients 3 years of age and older. The medication is used for patients without cirrhosis or with compensated cirrhosis, and in combination with ribavirin for those with decompensated cirrhosis. It is also approved for certain patients co-infected with HIV-1 and for liver transplant recipients.

Boxed Warning

The FDA requires a boxed warning for Harvoni due to the risk of hepatitis B virus (HBV) reactivation. In patients infected with both HCV and HBV, starting treatment with direct-acting antivirals like Harvoni may cause the hepatitis B virus to become active again. This reactivation can result in serious liver injury, liver failure, or death. Healthcare providers are required to screen all patients for evidence of current or prior HBV infection before beginning therapy and monitor for flare-ups during and after treatment.

Safety Communications

The FDA has issued safety communications regarding the use of Harvoni with certain other medications. A significant concern involves the risk of serious symptomatic bradycardia (a dangerously slow heart rate) when Harvoni is taken in combination with amiodarone, a drug used to treat heart rhythm disorders. This interaction can be life-threatening and may require medical intervention or the use of a pacemaker. Additionally, the FDA monitors adverse event reports to identify potential new safety signals, such as skin reactions or other systemic issues, as part of its ongoing regulatory oversight.

Question 11

What should I know about Harvoni and cost?

Accepted Answer

Factors Influencing Cost

The total price of Harvoni treatment is primarily determined by the duration of the prescription, which typically lasts 8, 12, or 24 weeks. Other factors include:

Insurance Coverage: Out-of-pocket costs vary widely between different private insurance plans, Medicare, and Medicaid.
Generic Options: A generic version containing the same active ingredients (ledipasvir and sofosbuvir) is available and may be more affordable than the brand-name product.
Pharmacy Choice: Prices can differ between retail pharmacies and specialty pharmacies.

Insurance Requirements

Because Harvoni is a high-cost specialty medication, most insurance companies require a process called prior authorization. This means your doctor must submit documentation to your insurance provider to confirm that the medication is medically necessary before the plan will agree to cover the cost.

Financial Assistance Programs

For individuals who are uninsured or whose insurance does not fully cover the cost, there are options to help manage expenses:

Patient Assistance Programs: The manufacturer may provide the medication at a reduced cost or for free to patients who meet specific income and eligibility requirements.
Co-pay Cards: Patients with commercial insurance may be eligible for co-pay coupons that lower the amount paid at the pharmacy counter.

Harvoni

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Harvoni

Hospitals.net Disclosure